Podcasts about neurovascular

Rahul Sidhu, narrating a new blog he wrote for the Dementia Researcher website. Rahul's blog explores his research and the connection between heart disease and Alzheimer's disease, focusing on how vascular dysfunction may accelerate cognitive decline. He explains the importance of neurovascular coupling, the role of tau protein tangles, and how conditions like atherosclerosis impact brain health. Using preclinical models, his research investigates whether impaired blood flow worsens Alzheimer's progression, highlighting the potential for new treatments that improve vascular health as a way to slow or prevent dementia. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-my-phd-neurovascular-effects-of-heart-disease-in-alzheimers/ -- ​Rahul Sidhu is a PhD student at The University of Sheffield, focusing on the effects of heart disease on dementia in preclinical models of Alzheimer's disease. His research aims to uncover how cardiovascular health influences neurodegenerative conditions, potentially leading to novel therapeutic strategies.​ Find Rahul on LinkedIn -- Enjoy listening? We're always looking for new bloggers, drop us a line. http://www.dementiaresearcher.nihr.ac.uk This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social

In this episode, we have the pleasure to host Matt Sturt, Vice President Neurovascular & Pelvic Health at Medtronic, for an in-depth conversation where Matt shares how his early days as a sales representative at Vygon in the UK and his transition to Medtronic shaped his perspective and leadership style. He highlights the pivotal moments in his career, including his move from local to regional roles and later into global leadership positions, which broadened his understanding of the complexities of managing diverse teams and responsibilities.Matt emphasizes the transformative power of commercial excellence in building high-performing teams and driving business success. Drawing on his experience across regions such as Europe, the US, and Asia, he underscores the importance of understanding and adapting to cultural differences to foster collaboration and achieve shared goals. He passionately discusses authenticity in leadership, stressing the importance of staying true to one's principles and values while balancing corporate expectations.The conversation explores the challenges of leading through unprecedented times, such as the COVID-19 pandemic, and the lessons Matt learned about resilience, emotional intelligence, and focusing on what truly matters. He provides practical advice for aspiring leaders, encouraging them to seek diverse experiences, learn from others, and embrace authenticity as a cornerstone of effective leadership.On a personal note, Matt shares how he maintains balance amidst a demanding global role. He offers tips for smart travel, staying healthy, and focusing on longevity, both professionally and personally.The episode provides a blend of personal insights and actionable leadership advice. Matt's reflections on authenticity, adaptability, and continuous learning offer a roadmap for effective leadership in a complex, globalized world.Please do not hesitate to share your feedback with us on our LinkedIn or Instagram pages and to give us a rating on Apple Podcast. This is very important to help us grow The Leadership Consultation community...  

Many of us will experience a migraine - or many migraines - in our life. If you ever have, you know it's not fun and can affect your entire day. Dr. Rani Banik is a board-certified neuro-ophthalmologist and bestselling author who focuses on the root cause of migraines and uses strategies based on nutrition, botanicals, lifestyle modification, and supplements. Join us as she uncovers the difference between migraines & regular headaches, potential triggers of migraines, what puts you at a higher likelihood of getting migraines including genetics, how to prevent migraines, and how to keep your mental health & wellbeing in check despite getting migraines. Follow Dr. Rani Banik on Instagram @Dr.RaniBanik and check out her book & supplements: Beyond Carrots: Best Foods For Eye Health A to Z Shop Ageless Eyes Supplements The Migraine Bundle Follow & Subscribe to Uncover Your Eyes on your favorite podcast platform and YouTube, and learn more about Dr. Meenal on Instagram @Dr.MeenalAgarwal

In this episode of Neuro Innovation Talks, host John Murray interviews Charles "Chuck" Kerber, MD, Emeritus Professor of Radiology and Neurosurgery at UCSD, a pioneering force in neurovascular medicine, whose innovations—such as flow-directed catheters and cyanoacrylates for therapeutic embolization—transformed the field. Dr. Kerber reflects on his Appalachian roots and military experience, highlighting how these influences shaped his views on responsibility, mentorship, and patient-centered care. His philosophy of innovation, grounded in imagination and resilience, offers a blueprint for tackling complex medical challenges. The discussion explores the iterative process of developing life-saving neurovascular devices, from early failures to groundbreaking successes, and emphasizes the vital role of collaboration with industry partners. Dr. Kerber shares stories of his mentorship style, which encouraged creativity and accountability, and its profound impact on the next generation of neurovascular physicians. He also underscores the importance of ethical considerations and humanity in patient care. Looking ahead, Dr. Kerber advocates for the continued integration of creativity and teamwork in addressing future neurovascular challenges. He closes by offering young physicians advice on embracing imagination and perseverance to drive innovation and improve patient outcomes. Thank you to Resonetics for sponsoring this episode of Structural Heart Talks. To learn more about how Resonetics supports medical device companies, visit: https://shorturl.at/E1wO8 Special thanks to the following for their support in the development of this podcast: Joanna Colangelo, Mark Dickinson, Whitney Garrett, Tracy Murray, SYK, Eytan Raz, MD, Boris Pabon, MD, Joseph Horton, MD, John Barr, MD, and special thanks to William Bank, MD. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks to never miss an episode. Thank you for supporting the Neuro Innovation Talks podcast!

Join Kahliana Nguyen and Khaled Najjar, Translational and Molecular Medicine students, as they speak with Dr. Baptiste Lacoste, a neuroscience researcher at the Ottawa Hospital Research Institute whose recent work focuses on the critical role of the brain's vascular system in development.  The episode explores a new perspective on autism spectrum disorders (ASD) and how problems with the brain's blood vessels in early development may contribute to challenges seen in autism. Dr. Lacoste goes into depth on how these blood vessels play a role in brain growth, energy use, and behavior. By studying these interactions alongside neural and genetic factors, his research opens new avenues in how we understand autism and find better ways to address ASD. Whether you're a researcher, student, or simply curious, this episode offers an exciting new lens to the field. Learn more: Dr Baptiste Lacoste Dr Baptiste Lacoste | Faculté de médecine https://bsky.app/profile/blacoste.bsky.socialhttps://www.ohri.ca/profile/lacostelab0:02 | BEaTS and host introduction.0:22 | Introduction to Dr. Lacoste1:10 | Why did Dr. Lacoste choose to focus on the vascular system specifically?3:05 | The Neurovascular unit (NVU) and its importance in Dr. Lacoste's research on ASD5:15 | The use of mice with a 16p11.2 deletion mutation to study ASD8:43 | The novel findings were seen in Dr. Lactoste's lab study on ASD10:51 | Treatment Strategies when it comes to ASD12:03 | Limitations & Challenges Dr. Lacoste's lab faced and still faces while studying ASD13:50 | Wrapping up the episodeScience and Innovation by Vicate. All rights reserved. Listen more:https://www.jamendo.com/album/578641/science-and-innovationVicate | Jamendo Music | Free music downloadsKahliana Nguyen (Voice) & Khaled Najjar (Producer & Editor)

In this episode of Neuro Innovation Talks, Host John Murray interviews Professor Jacques Moret, MD, Professor and Consultant Interventional Neuroradiology and Honorary Chairman, NEURI center, Bicetre University Hospital, a pioneer in neurovascular intervention, as he reflects on the early challenges and groundbreaking innovations that shaped the field. Dr. Moret recounts the origins of balloon remodeling for brain aneurysm treatment, detailing the iterative process of developing this transformative technique and the critical role of collaboration with industry leaders. He highlights the technological and ethical considerations that informed his work, emphasizing the balance between innovation and patient safety. The conversation delves into his philosophy of mentorship, the significance of anatomical knowledge in neurointervention, and the importance of maintaining humanity in patient care. Dr. Moret also discusses the future of neurovascular treatment, advocating for MRI-compatible devices and real-time functional imaging to enhance procedural outcomes. Thank you to Confluent Medical Technologies for sponsoring this episode of Neuro Innovation Talks. To learn more about how Confluent Medical supports medical device companies, visit: www.confluentmedical.com. Special thanks to the following, the Neuro Innovation Talks podcast series would not be possible without their support: Joanna Colangelo, Mark Dickinson, Whitney Garrett, Tracy Murray, SYK, Dr. Christophe Cognard, Dr. Laurent Spelle, and Dr. Vitor Pereira Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks to never miss an episode. Thank you for supporting the Neuro Innovation Talks podcast!

In this episode of Neuro Innovation Talks, Head of Global Strategic Marketing and Strategic Relationships at Johnson & Johnson MedTech Neurovascular, John Murray, returns to the DeviceTalks podcast studio to spotlight one of the foremost pioneers in neurointervention, Fernando Vinuela, MD, Professor Emeritus of UCLA Interventional Neuroradiology. Dr. Vinuela shares his journey through the groundbreaking evolution of neurovascular treatments and the collaborative spirit that propelled early advancements in stroke care. From his foundational work on detachable coils to his transformative mentorship, Dr. Vinuela reflects on his contributions to neurointervention and the significant milestones that have shaped the field. He also provides insights into his impactful work in Brazil, where he has helped establish stroke treatment programs, expanding the reach of life-saving neurovascular care. Thank you to Confluent Medical Technologies for sponsoring this episode of Neuro Innovation Talks. To learn more about how Confluent Medical supports medical device companies, visit: https://confluentmedical.com. Special thanks to the following for their support in the development of this podcast: Joanna Colangelo, Mark Dickinson, Whitney Garrett, Tracy Murray, SYK, Dr. Vinuela, Dr. Satoshi Tateshima, Dr. Dileep Yavagal. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks to never miss an episode. Thank you for supporting the Neuro Innovation Talks podcast!

In this episode of Neuro Innovation Talks, the newest podcast series in the DeviceTalks Podcast Network, the DeviceTalks editors invite Johnson & Johnson MedTech Neurovascular's Head of Global Marketing, John Murray to take over the podcast studio and bring to light the stories from the pioneering neurointerventionalists who have helped shape the stroke industry. In the first episode, Host John Murray sits down with Alejandro Berenstein, MD, Professor of Neurosurgery, Pediatrics and Radiology, Director of pediatric Cerebrovascular Surgery, Mount Sinai Health System, to discuss the incredible evolution of neurovascular surgery and its impact on modern healthcare. Dr. Berenstein shares his early inspirations, key breakthroughs, and the significant role mentors played in shaping his illustrious career. Highlighting landmark projects like the pioneering treatments for Vein of Galen Malformations (VOGM) and facial vascular anomalies, Dr. Berenstein shares the complexities and triumphs of his work. His story provides a blueprint for aspiring medical professionals and innovators, demonstrating how personal experiences, visionary thinking, and collaborative efforts can lead to groundbreaking advancements that significantly impact patient outcomes. Thank you to Zeus for sponsoring this episode of Neuro Innovation Talks. To learn more about how Zeus supports medical device companies, visit: www.zeusinc.com. Special thanks to the following for their support in the development of this podcast: Joanna Colangelo, Johanna Fifi, Whitney Garrett, Howard Riina, Lillian Medina, and J. Mocco. Tune in and subscribe to the DeviceTalks Podcast Network wherever you get your podcasts and follow youtube.com/@DeviceTalks to never miss an episode. Thank you for supporting the Neuro Innovation Talks podcast!

In this enlightening episode of Research Renaissance, host Deborah Westphal engages in a compelling conversation with Dr. Elisa Canepa, a neurobiologist and associate scientist from Temple University and a 2022 Toffler Scholar. Dr. Canepa shares her journey into neuroscience, driven by a fascination with the brain's complexity and its pivotal role in shaping our identity and cognitive functions. They delve into Dr. Canepa's cutting-edge research on cerebral vascular dysfunction, particularly focusing on the potential of carbonic anhydrase inhibitors (CAIs) in treating Alzheimer's disease.Key Discussion Points:Introduction to Dr. Elisa Canepa:Background and inspiration for pursuing neuroscience.Current role at Temple University and involvement with the Karen Toffler Charitable Trust.Research Focus:Investigation into the role of carbonic anhydrase inhibitors in Alzheimer's treatment.Mechanisms behind CAIs' ability to rescue cognitive functions and ameliorate neurovascular dysfunction.Recent findings published in the Alzheimer's and Dementia Journal.Experimental Techniques:Behavioral tasks to measure cognitive impairment and the effectiveness of treatments in animal models.Advanced techniques like RNA sequencing and RNA scope to study the molecular changes in the brain.Impact of High Altitude Physiology:Exploration of the physiological differences in people living at high altitudes and potential insights for Alzheimer's research.Future Directions and Challenges:Potential clinical applications and the pathway to clinical trials for CAIs.The importance of interdisciplinary collaborations and combining different expertise to advance research.The role of biomarkers and advanced imaging techniques in predicting and diagnosing neurological diseases.Personal and Professional Insights:Dr. Canepa's reflections on the importance of raising awareness about Alzheimer's disease.The significance of combining basic science research with outreach and advocacy efforts.The global nature of neurodegenerative research and collaborations across countries.Emerging Research Areas:Investigations into tauopathies and their impact on vascular health.The intersection of cardiovascular health and Alzheimer's disease, particularly in the context of Western diets and lifestyle factors.Join us in advancing our understanding of the brain and addressing its ailments. Until then, onward and upward!To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

In this episode of Research Renaissance, host Deborah Westphal engages in an enlightening conversation with Ashley Carey, a PhD candidate and 2023 Toffler Scholar at Temple University's Lewis Katz School of Medicine. Ashley's research focuses on the neurovascular dysfunction and neuroinflammation associated with Alzheimer's disease. She shares her journey from aspiring marine biologist to neuroscience researcher, highlighting the importance of cardiovascular health in preventing Alzheimer's.Guest Introduction: Ashley CareyAshley Carey is a PhD candidate and graduate research assistant in Dr. Silvia Fossati's lab at Temple University. She is also a 2023 Toffler Scholar. Her research examines the impact of cardiovascular risk factors on Alzheimer's disease, specifically focusing on neurovascular dysfunction and neuroinflammation. Ashley's work aims to understand how conditions like hyperhomocystinemia and hypertension contribute to Alzheimer's pathology.Key Discussion PointsCareer Motivation and Journey:Ashley's transition from an interest in marine biology to neuroscience during undergraduate schoolThe influence of Dr. Reynolds at Lafayette College in sparking her interest in research.Her decision to focus on Alzheimer's disease during her PhD program at Temple University.Research Focus:Examining cardiovascular risk factors like hyperhomocystinemia and hypertension in Alzheimer's disease.Recent publication on endothelial cell dysfunction due to amyloid beta and homocysteine exposure.The role of cerebral endothelial cells in maintaining vascular integrity and their impact on Alzheimer's pathology.Significant Findings:Additive effects of homocysteine and amyloid beta on endothelial cell dysfunction and increased permeability.The importance of vascular health in preventing early neuronal damage and cognitive decline.Challenges in Alzheimer's Research:Difficulty in obtaining sufficient model samples due to the aging process and cardiovascular risk factors.Complexity of brain vasculature and overlapping pathways complicating research.Funding challenges and the impact of decreased NIA pay lines on dementia research.Interdisciplinary Collaborations:Collaborative work with behavioral testing and biomarker studies.Contributions from the lymphatics department, investigating amyloid deposition in peripheral vessels.Future Directions and Aspirations:Ashley's goal to contribute to neurodegenerative disease research, possibly transitioning into a company or academia.The potential impact of early detection techniques and biomarker screening on Alzheimer's diagnosis and treatment.Mentoring and Funding:Ashley's experience with mentorship from Dr. Fossati and its importance in her research journey.The role of the Toffler Scholar Grant  in supporting her research and supporting career goals.Stay tuned for more episodes of Research Renaissance by subscribing to our podcast. For further information and updates, visit our website at TofflerTrust.org. We welcome your thoughts and suggestions, so feel free to reach out!Until then, onward and upward!To learn more about the breakthroughs discussed in this episode and to support ongoing research, visit our website at tofflertrust.org. Technical Podcast Support by Jon Keur at Wayfare Recording Co.

Studies have shown a close interplay between the cerebrovascular system and neurodegeneration. But what is the current evidence, and how can it help us better understand the pathophysiology of Lewy body disorders and potentially change their course? In this episode, Dr. Michele Matarazzo interviews Prof. Sephira Ryman about a recently published review article that explores the complexities of this relationship. Read the article.

Andy discusses his background growing up on a farm and how it shaped his work ethic. He talks about his experience founding Engineering Consultants and working with medical device startups. Key topics include challenges in commercializing devices, balancing an inventor's vision with engineering feasibility, and advice for engineers entering the field.Main Topics: Medical device regulationsChallenges in commercializationBalancing an inventor's visionStem cell and gene therapy advances in ophthalmologyAdvice for young engineers About the guest: Andy Schieber is a seasoned medical device engineer and entrepreneur with extensive experience in research and development. He is the Founder and President of Ingenarious Consultants, a firm that specializes in early-stage medical device development, offering services from concept to clinical trials. Andy has a remarkable track record in designing and developing Class III implantable medical devices, and he holds over 40 patents including the Hydrus Microstent, which is a significant innovation in ophthalmology.He also serves as the Head of Engineering at Rivermark Medical, where he contributes to the development of novel medical technologies. Andy's educational background includes a Master's degree in Mechanical Engineering from the University of Minnesota and a Bachelor's in Engineering from the University of Wisconsin-Stout​.Links:Andy Schieber - LinkedInIngenarious Consultants WebsiteAbout Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

Strokes are caused by blocked blood flow to the brain (ischemic stroke) or sudden bleeding in the brain (hemorrhagic stroke). About 87% of strokes are ischemic with the blockage in the brain usually caused by a piece of plaque or a blood clot. Like fingerprints, no two strokes are the same. Yet, conventional therapy options are limited and can compromise patient safety.​​ Rapid Medical's CEO and co-founder, Ronen Eckhouse joins this episode to share how they are bringing critical innovation to tackle ischemic strokes and enable physicians to respond in real-time to the brain's complex anatomy, helping tailor the procedure to every patient. Rapid Medical's uniquely designed stent is hard on the clot but soft on the vessel, this allows physicians to actively adapt to the fragile environment found in the brain. Ronen shares how the company has built value through strong partnerships, a growing patent portfolio, and ultimately helped bring enhanced outcomes for stroke patients in countries across the globe. With a long-term mission to solve big problems and some exciting new innovation on the horizon, Ronen's journey is one sure to leave you informed and inspired.

Dr Beth Eyre narrates her blog written for Dementia Researcher. Beth reflects on her enriching journey from a PhD student to a postdoctoral researcher, in this heartfelt farewell blog. Beth shares insights from her experiences, the challenges of experimental failures, and the lessons learned in resilience and self-belief. As she prepares for a new role in Boston, USA, specialising in brain clearance and cerebral amyloid angiopathy, she shares her anticipation for future learning and her commitment to supporting upcoming researchers. This blog shares the essence of her academic and personal growth, emphasising the importance of perseverance and community in scientific discovery. As we say goodbye, Beth concludes with gratitude to the listeners and readers of her blogs, and shares her excitement for her next adventure in dementia research. Join her as she steps into this new chapter, continuing to contribute passionately to the field. After a little more than 3 years, and 32 blogs charting the early days of her PhD to finding a great postdoc position, it has been wonderful to work with Beth. We hope you will join us in thanking her for taking us along with her on her PhD journey - post your comments below and leave a review. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-its-not-the-end-its-a-new-beginning/ Find all Beth's blogs on on our website.   -- Dr Beth Eyre is a Postdoctoral Researcher at The University of Sheffield, researching Neurovascular and cognitive function in preclinical models of Alzheimer's disease. Beth has a background in psychology, where she gained her degree from the University of Leeds. Inside and outside the lab, Beth loves sharing her science and in her blogs, she discusses her work, career and shares lessons she learns as she navigates life as an early career researcher. -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. Enjoy listening? We're always on the look out for new contributors, if you would like to write and narrate your own blog - drop us a line dementiaresearcher@ucl.ac.uk.  Don't forget to also listen to our fortnightly podcast, just look for Dementia Researcher in your podcast app. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher

Dr Beth Eyre narrates her blog written for Dementia Researcher. Beth's blog discusses the advancing field of using retinal imaging as a biomarker for Alzheimer's disease (AD), bringing highlights from the recent ISTAART Eye as a Biomarker for AD PIA, year in review. The session highlighed the eye's potential for non-invasive early detection. Recent studies showcase the retina's susceptibility to AD changes, mirroring brain pathology, which could be observed using high-resolution imaging akin to standard optician equipment. Notably, retinal vascular changes in high-risk patients, as well as the use of 3D-organoid models, suggest the retina's significant role in monitoring and detecting AD, marking an exciting era for this research. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-eye-as-a-biomarker-for-ad-pia-year-in-review-recap/ Don't forget, you can get involved in the Eye as a Biomarker for AD PIA by joining ISTAART and get access to previous webinars! -- Dr Beth Eyre is a Postdoctoral Researcher at The University of Sheffield, researching Neurovascular and cognitive function in preclinical models of Alzheimer's disease. Beth has a background in psychology, where she gained her degree from the University of Leeds. Inside and outside the lab, Beth loves sharing her science and in her blogs, she discusses her work, career and shares lessons she learns as she navigates life as an early career researcher. -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. Enjoy listening? We're always on the look out for new contributors, if you would like to write and narrate your own blog - drop us a line dementiaresearcher@ucl.ac.uk.  Don't forget to also listen to our fortnightly podcast, just look for Dementia Researcher in your podcast app. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://bsky.app/profile/dementiaresearcher.bsky.social https://www.linkedin.com/company/dementia-researcher

Dr Beth Eyre narrates her blog written for Dementia Researcher. Beth brings us news from last months ISTAART Subjective Cognitive Decline PIA Year in Review Webinar. The event explored the latest advancements in subjective cognitive decline (SCD) research, emphasising its significance as an early indicator for Alzheimer's disease. Beth highlights new findings that deepen understanding of SCD's role in Alzheimer's progression, including potential biomarkers and the impact of early intervention strategies. These insights are crucial for developing more effective treatments and preventive measures, underscoring the importance of continued research and collaboration in the field.  Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-biofluid-based-biomarkers-pia-year-in-review-recap/ Don't forget, you can get involved in the SCD PIA by joining ISTAART and get access to previous webinars! -- Dr Beth Eyre is a Postdoctoral Researcher at The University of Sheffield, researching Neurovascular and cognitive function in preclinical models of Alzheimer's disease. Beth has a background in psychology, where she gained her degree from the University of Leeds. Inside and outside the lab, Beth loves sharing her science and in her blogs, she discusses her work, career and shares lessons she learns as she navigates life as an early career researcher. -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. Enjoy listening? We're always on the look out for new contributors, if you would like to write and narrate your own blog - drop us a line dementiaresearcher@ucl.ac.uk.  Don't forget to also listen to our fortnightly podcast, just look for Dementia Researcher in your podcast app. -- Follow us on Social Media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://twitter.com/demrescommunity https://bsky.app/profile/dementiaresearcher.bsky.social https://www.linkedin.com/company/dementia-researcher

Welcome to “At the Bench” a new podcast in the Incubator network focusing on physician-scientists in neonatology, their research, and career journeys. This week, we start by interviewing Dr. Elizabeth “Betsy” Crouch, a neonatologist, neuroscientist, and vascular biologist at the University of California, San Francisco. Dr. Crouch's lab takes a “Vascular-centric” perspective to neurodevelopment and studies how the blood vessels in the developing brain and spinal cord impact the growing neural cells, and vice versa. In part, this approach is inspired by germinal matrix hemorrhage, a devastating condition unfortunately common in the NICU that can cause cerebral palsy, hydrocephalus, and death. Early in Dr. Crouch's training, a family she cared for in the NICU questioned the status quo in germinal matrix hemorrhage management. They asked why, in this era of modern medicine, their baby had no treatment options for this devastating and common condition. This anecdote highlights what has become a theme in her research: basic and translational science inspired by parents and patients. Her lab now focuses on defining the stages of vascular stem cells in the developing brain and understanding the mechanisms that regulate their functions, applying this knowledge to produce novel technologies and therapeutic strategies for different brain hemorrhages in neonatal and pediatric patients. This episode discusses the challenges and victories in Dr. Crouch's journey, her mentors and their wisdom, and how we might create a future without germinal matrix hemorrhage for our premies and their families.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Beth Eyre narrates her blog written for Dementia Researcher. Beth reflects on her nearly one-year experience as a post-doc, highlighting the lack of control in research projects, the significant responsibilities of the role, the never-ending tasks, the importance of time management, and the constant uncertainty of what's next in an academic career.... Sound familiar? She acknowledges the dynamic nature of science and the need to adapt to changing priorities and circumstances, ultimately emphasising the uniqueness of each individual's journey in academia. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-reflections-on-my-kind-of-first-year-as-a-post-doc/ -- Dr (pending minor amendments) Beth Eyre is a Postdoctoral Researcher at The University of Sheffield, researching Neurovascular and cognitive function in preclinical models of Alzheimer's disease. Beth has a background in psychology, where she gained her degree from the University of Leeds. Inside and outside the lab, Beth loves sharing her science and in her blogs, she discusses her work, career and shares lessons she learns as she navigates life as an early career researcher. -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. Enjoy listening? We're always on the look out for new contributors, if you would like to write and narrate your own blog - drop us a line dementiaresearcher@ucl.ac.uk.  Don't forget to also listen to our fortnightly podcast, just look for Dementia Researcher in your podcast app.

In this episode of StrykerTalks, neurovascular president Jim Marucci discusses the company's latest advancements in neurovascular technology and how that, and its expanding global footprint, are shaping the future of its neurovascular division. Marucci details the company's recent strategic acquisition of Cerus Endovascular, which has increased Stryker's capabilities in treating wide-neck bifurcated aneurysms. Furthering Stryker's goal to simplify procedures, reduce costs, and improve patient outcomes. The conversation also touches on developing new products like the Target Tetra detachable coil for smaller aneurysms and the potential of emerging technologies like AI, AR, and VR in neurovascular procedures. Marucci anticipates these technologies will play a crucial role in advancing the field and improving access to care globally. Tune in for a comprehensive overview of Stryker's current strategies, product innovations, and future directions in the neurovascular sector, underlining its commitment to enhancing stroke care and neurovascular treatments worldwide. Thank you to Zeus for sponsoring this episode. To learn more about how Zeus works with medical device companies, visit www.zeusinc.com. Thank you for listening to the StrykerTalks Podcast. Subscribe to this podcast on every major podcast platform.

In one of 1PM's most requested episodes, tune in to hear returning presenter Nic Ellison go through Orthopaedic Triage. Join Navi, Jay and Jason, as they work out what to fix first in the world of broken bones. === Other Links === Check out our new website ⁠⁠⁠⁠⁠⁠⁠⁠⁠1pm.wiki⁠⁠⁠⁠⁠⁠⁠⁠⁠ for the ⁠⁠⁠⁠⁠⁠⁠⁠⁠Notion document⁠⁠⁠⁠⁠⁠⁠⁠⁠, free Anki flashcards, and podcast episodes. Check out our Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/firstprinciplesofmedicine/⁠⁠⁠⁠⁠⁠⁠⁠⁠ Recorded 5 November 2023 Co-hosts: Nic Ellison, Jason D'Silva, Navi Cheyurr & Jay Cheyurr. Produced by Adian Izwan. If you have any ideas or feedback, comment on this Notion document, or shoot us an email at ⁠⁠⁠⁠⁠⁠⁠⁠hello@1pm.wiki⁠⁠⁠⁠⁠⁠⁠⁠ *** We're really excited to be collaborating with Becky from Becky's notes, a UK based resource, to produce infographics for our visual learners out there. Becky's notes brings together all the key topics medical students need to know in a readily available place, reviewed by specialists in the field. These visually striking notes are a refreshing change from all the boring textbooks. You can check her out on Instagram at @beckysnotes01 and get her books at ⁠⁠⁠⁠⁠⁠⁠⁠⁠https://linktr.ee/Beckysnotes⁠⁠⁠⁠⁠⁠⁠⁠⁠ === Timestamps === (00:54) Triage stations (01:45) What is Triage? (02:47) Preliminary assessment (03:38) Tip 1: the angry patient (04:51) Classic Ortho conditions (05:38) Stratifying fractures (06:33) MVA - high energy trauma (07:11) Compartment syndrome (08:28) Septic arthritis (09:49) Less serious fractures (11:15) Infected prostheses (11:54) Scaphoid fractures (12:49) Tip 2: look at the vitals (14:31) Investigations – X-Rays (17:51) How to use the reading time (19:50) Management (25:48) Septic arthritis and septic shock (27:17) Nic's management spiel (29:05) Neurovascular assessment recap

Beth Eyre narrates her blog written for Dementia Researcher. To make your PhD application stand out, Beth advises crafting a detailed academic CV that highlights specific interests and experiences relevant to the PhD, and supplementing it with a personal statement that conveys genuine enthusiasm for the subject. She emphasises the importance of demonstrating this interest through actions like attending webinars or joining professional societies, such as ISTAART for Alzheimer's research. Sharing pertinent research experience and expressing a clear rationale for wanting to work in a particular lab or university are also key to differentiating your application from others. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-how-to-make-your-phd-application-stand-out/ -- Dr (pending minor amendments) Beth Eyre is a Postdoctoral Researcher at The University of Sheffield, researching Neurovascular and cognitive function in preclinical models of Alzheimer's disease. Beth has a background in psychology, where she gained her degree from the University of Leeds. Inside and outside the lab, Beth loves sharing her science and in her blogs, she discusses her work, career and shares lessons she learns as she navigates life as an early career researcher. -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. Enjoy listening? We're always on the look out for new contributors, if you would like to write and narrate your own blog - drop us a line dementiaresearcher@ucl.ac.uk.  Don't forget to also listen to our fortnightly podcast, just look for Dementia Researcher in your podcast app.

Season Two of Small Brains, Big Dreams continues our conversations around mentorship with leading neurologists from around the world. Dr. Lina Chalak has many accomplishments and accolades in her biography, but she's quick to point out the award from UT Southwestern celebrating her work as a mentor holds a special place of honor for her. Listen as she shares her ‘why' and encourages you to do the same.Dr. Lina Chalak (MD, MSCS) is the founding director of both the Neurointensive Care program and the Fetal Neonatal Neurology Fellowship Program at UT Southwestern, where she holds the William Buchanan Chair in Pediatrics and serves as the Interim Chief of Neonatal-perinatal Medicine. She is a Professor in the Departments of Pediatrics and Psychiatry at UT Southwestern Medical Center and an active researcher.Dr. Chalak is board certified in general pediatrics, general pediatrics recertification, neonatal-perinatal medicine, and neonatal-perinatal recertification. She earned her medical degree and completed a residency in pediatrics at American University of Beirut, then fellowships in both neonatal-perinatal medicine and pediatrics at UT Southwestern/Children's Health Dallas. In 2011, she received a Master of Clinical Science Distinction from UT Southwestern's Graduate School of Biomedical Sciences, and in 2021 she earned the school's Best Mentor Award.Dr. Chalak's research focuses on asphyxia, hypothermia, and neonatal brain injury. She led the PRIME mild asphyxia collaborative study and pioneered a Neurovascular bundle for a critical real time evaluation of the coupling of cerebral blood flow and neuronal activity in newborns with asphyxia.For more on Dr. Chalak:https://newbornbrainsociety.org/team-member/lina-f-chalak-md-mscs/Small Brains, Big Dreams is a podcast created by the Newborn Brain Society, in partnership with the Canadian Premature Babies Foundation, and hosted by preemie parent & journalist, Jenna Morton.The Newborn Brain Society is a non-profit organization supporting a world in which all newborns have access to and receive the optimal brain care. We promote international, multi-disciplinary collaboration, education, and innovation among clinicians, scientists, and parents.Connect with us at newbornbrainsociety.org, on Facebook @NewbornBrainSociety, and on Twitter @NewbornBrains.If you've enjoyed this episode, please rate, share & subscribe.

Beth Eyre narrates her blog written for Dementia Researcher. Navigating the labyrinthine world of doctoral research? Beth is our go-to source for demystifying the process. Whether you're set on a specific research question or just know the academic field you want to explore, Beth's comprehensive guide lays out practical steps to find the PhD programme that's right for you. From the utility of websites like findaphd.com, which lists thousands of PhD opportunities worldwide, to the advantages of using social media platforms like X to connect with key researchers (and the Dementia Researcher website), she offers a variety of methods to help you find your perfect match. The blog even includes tips on how to directly approach research group leaders and delves into the specifics of Doctoral Training Programmes (DTPs). It's a must-read for anyone serious about pursuing a PhD. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/blog-how-to-find-a-phd-an-insiders-guide/ -- Dr (pending minor amendments) Beth Eyre is a Postdoctoral Researcher at The University of Sheffield, researching Neurovascular and cognitive function in preclinical models of Alzheimer's disease. Beth has a background in psychology, where she gained her degree from the University of Leeds. Inside and outside the lab, Beth loves sharing her science and in her blogs, she discusses her work, career and shares lessons she learns as she navigates life as an early career researcher. -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. Enjoy listening? We're always on the look out for new contributors, if you would like to write and narrate your own blog - drop us a line dementiaresearcher@ucl.ac.uk.  Don't forget to also listen to our fortnightly podcast, just look for Dementia Researcher in your podcast app.

Beth Eyre narrates her blog written for Dementia Researcher. Beth provides an essential guide for anyone considering embarking on a doctoral journey. As she approaches the culmination of her own PhD, Beth breaks down the often perplexing aspects of a PhD, from its basic definition to the stages involved and even how to secure funding. Offering a detailed account of what to expect in each year of the programme and the roles one will play, the blog addresses common uncertainties. By elaborating on the application process, different types of PhDs like Doctoral Training Programmes (DTPs), and the unique challenges and opportunities posed by the independent nature of the research, This blog is a prospective roadmap to a fulfilling doctoral experience. Find the original text, and narration here on our website. https://www.dementiaresearcher.nihr.ac.uk/guest-blog-demystifying-the-phd/ -- Dr (pending minor amendments) Beth Eyre is a Postdoctoral Researcher at The University of Sheffield, researching Neurovascular and cognitive function in preclinical models of Alzheimer's disease. Beth has a background in psychology, where she gained her degree from the University of Leeds. Inside and outside the lab, Beth loves sharing her science and in her blogs, she discusses her work, career and shares lessons she learns as she navigates life as an early career researcher. -- This podcast is brought to you in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia, who we thank for their ongoing support. Enjoy listening? We're always on the look out for new contributors, if you would like to write and narrate your own blog - drop us a line dementiaresearcher@ucl.ac.uk.  Don't forget to also listen to our fortnightly podcast, just look for Dementia Researcher in your podcast app.

Powerful Practices to Transmit and Engender a Passion for Purpose from an Extraordinary Leader Mark Paul, Builder and Recent President, Stryker Neurovascular, Now Executive Director, Center of Medical Innovation, University of Utah Health. See more at: MarkSpencerCook.com/Podcast/ and subscribe. Mark Paul spoke with surprising expertise about leading people and brains to success. "Unleashing curiosity's fire ignites a path to extraordinary success." "Unlocking the power of focus transforms lives, one purposeful step at a time." "A symphony of innovation awaits as the baton is passed to the future's brilliant minds." "Build bridges of care. Friendships heal beyond borders." -Mark Paul Find: ⁠Mark Paul⁠ at https://www.linkedin.com/in/mark-paul-7a650463/ In this episode of Bold Encounters, Mark Paul shares his career journey from Procter & Gamble through the medical device industry. He discovered his mission-oriented nature, desire to help people, and how to relieve suffering and save families and lives. Mark Paul values human connection. He leads others with genuine care and interest. He builds lifelong friendships with colleagues and emphasizes long-term investment and care in relationships. His expertise is stunning. Mark Paul approach to his career involved embracing new opportunities and continuously learning. He recognized that a college degree should not limit one's potential, and the skills and experiences gained over time hold incredible value. Mark Paul's success was driven by curiosity, passion, and the ability to deliver results. He took on challenging projects and products that others overlooked, finding creative ways to make them successful and interesting. Purpose, for Mark, was deeply connected to the patients he served. Mark Paul is focused on making a difference in stroke victims' lives, especially among women. While recognizing the importance of broader causes, Mark chose to prioritize his efforts where he could directly impact lives and families.  Mark highlights the prevalence of stroke among women and its significant impact on families. Mark's deep purpose lies in saving the lives of stroke patients and enabling them to regain their independence and help care, not require it, for their loved ones. Mark Paul works so that everyone in the organization shares a passion for the patient's well-being, regardless of their role. Mark also briefly discusses the symptoms of stroke, emphasizing the acronym "FAST" (Face, Arm, Speech, Time) to identify potential stroke symptoms and act quickly. Mark's team conducted clinical trials, including the groundbreaking Dawn study, which extended the treatment window for stroke patients, leading to a worldwide shift in treatment guidelines. Mark is committed to engendering camaraderie among team members as a crucial factor in achieving success. Mark Paul envisions a future where the Neurovascular division continues to make significant advancements in saving stroke patients and improving patient outcomes. He believes that the division is just starting and considers it in the golden era of the medical device industry. With the convergence of technologies such as nano-level design, imaging, artificial intelligence, and robotic assist. Mark remains excited about the future of healthcare and medical devices. Mark retired from Stryker but not from working. He has accepted a position at the University of Utah Medical Center as the Center of Medical Innovation director. In this role, he will work with physicians, engineering, business, and legal students to bring medical device ideas to life. Mark believes that the younger generation, who have grown up surrounded by innovation, will develop more innovations than ever before. Watch more episodes and find a transcript at: MarkSpencerCook.com/Podcast. Please, comment and subscribe.

Today's guest Yvette Dorsey, Associate Vice President of Academic Affairs at HCA Healthcare Capital Division and Nancy Boykin MBA, RN, MBA, CMSRN, CENP, Chief Nursing Officer, Retreat Doctors' Hospital talk with Randy Wilson about the next generation of nurses and health care professionals and issues that impact the African American culture. Yvette Dorsey, DNP, RN has a compelling record of leadership in nursing academia and in acute healthcare. She has been a nurse for over 20 years and obtained BSN from Chamberlain College of Nursing. She received an MSN from American Sentinel University, specializing in Nursing Education, and her Doctorate of Nursing Practice specializing in Healthcare Systems Leadership from Chamberlain College of Nursing in August 2016. Born in Richmond, Va, but calls St. Louis, Mo home, Yvette has worked in some of nursing's most complex and high acuity specialties. As a registered nurse, she worked 8 years in labor and delivery and she has over 8 years of experience working in critical care. Before starting a new role with the Capital Division, Yvette worked at Henrico Doctors Hospital – Forest where she started her leadership career in 2015 when she became the Perinatal Nurse Manager at HCA Commonwealth Perinatal Services; a OB/Antepartum practice with 5 locations throughout the Richmond market and worked with some of the nation's most recognized Perinatologists. After fulfilling the role of the Perinatal Nurse Manager, Yvette became the Nurse Manager and then Director for a 21 high-risk OB/Antepartum unit at Henrico, with oversight of the Perinatal Navigator Program in the Women's Hospital. The most recent role before transitioning to the Capital Division as Associate Vice President of Academic Affairs, Yvette was the Director of Oncology, Progressive Care Neurological Unit, and the Central Decision Unit which was the unit known to administer some of the first infusions in the outpatient setting during the pandemic for the MAB infusions in efforts of helping those diagnosed with COVID. Yvette also has a passion for nursing academia where she spent over 5 years as lead instructor for medical surgical, women and newborn health, and high-fidelity simulation in a hybrid program for both licensed practical nursing students and registered nursing students. Nancy Boykin is the Chief Nursing Officer/Chief Operating Officer at HCA Virginia's Retreat Doctors' Hospital. I have been a nurse for over 26 years and started my nursing career at Henrico Doctor's Hospital. My clinical background includes Medical/Surgical, Oncology, Telemetry, and Intensive Care Unit. My leadership career started as a Nurse Manager of a NeuroVascular Intensive Care Unit and a Nursing Director for several units including the NeuroVascular Intensive Care unit, NeuroVascular step-down unit, Medical Oncology, Surgical Oncology, Cardiac Medical Intensive Care Unit, Interventional Unit, and the Progressive Care Unit. My leadership has been identified by Corporate HCA and is one of a small group of people with particularly high performance and strong leadership skills to be included in the CNO Executive Development Program for 2015 where I then transitioned to the Associate Chief Nursing Officer position at Chippenham Hospital. I later became the Associate Chief Nursing Officer at Henrico Doctors' Hospital and for the last 7 years, I have been the Chief Nursing Officer of Retreat Doctors' Hospital. In May 2023, I took on a duo role and assumed additional responsibility and became the Chief Operating Officer. My goal in obtaining my DNP in May 2023 is to continue to advance the nursing practice to bring evidence-based knowledge into the practice arena, improve healthcare outcomes and strengthen the leadership role in guiding complex care delivery and nursing education.  

Full article: https://www.ajronline.org/doi/10.2214/AJR.23.29352  Transient ischemic attacks (TIAs) are very common in the United States, and prompt diagnosis of TIAs is important as they are associated with an increased risk of subsequent stroke. Jesi Kim, MD provides a discussion and critical analysis of an important article that demonstrates increased odds of subsequent stroke in patients who had incomplete neurovascular imaging after an emergency department encounter for TIA.

GUEST: Annemie Van Der Linden, AntwerpIn this edition of ‘Dive into Imaging Science' we discuss the brain and the mechanisms that it employs to clear unwanted waste material whilst we sleep with our former ESMI President and Emeritus Professor Annemie Van Der Linden - an outstanding figure and incomparable scientist.We learn how closely coupled this system - known as the glymphatics - is to blood circulation, and how physical stimulation can enhance glymphatic flow in anaesthetised but not awake mice. Along the way, we learn how curiosity and a wondering mind has led Annemie to use a wide range of models to study the brain, from fish to song birds.Selected Publication: Glymphatic influx and clearance are accelerated by neurovascular coupling. Holstein-Rønsbo S, Gan Y, Giannetto MJ, Rasmussen MK, Sigurdsson B, Beinlich FRM, Rose L, Untiet V, Hablitz LM, Kelley DH, Nedergaard M. Nat Neurosci. 2023 Jun;26(6):1042-1053. doi: 10.1038/s41593-023-01327-2. Publication reference: Holstein-Rønsbo S, Gan Y, Giannetto MJ, Rasmussen MK, Sigurdsson B, Beinlich FRM, Rose L, Untiet V, Hablitz LM, Kelley DH, Nedergaard M. Glymphatic influx and clearance are accelerated by neurovascular coupling. Nat Neurosci. 2023 Jun;26(6):1042-1053. doi: 10.1038/s41593-023-01327-2. Epub 2023 Jun 1. PMID: 37264158. https://www.nature.com/articles/s41593-023-01327-2Further information on the European Society for Molecular Imaging:https://e-smi.eu/Contact: office@e-smi.eu

Laser therapy has been proven to help with diabetic neuropathy pain, but could lasers stimulate damage reversal? Join us as we review the research on neurovascular function in diabetic neuropathy.Read the full research study mentioned in this episode.We do a live broadcast of the LTI Podcast every other week on Facebook. Watch this episode here. (Be sure to also catch our Healing at the Speed of Light Podcast on Facebook!)YouTube ChannelLaser Therapy InstituteFurther Resources:Success with Laser Therapy Flowchart & Checklist InfographicCheck out these FREE Provider ResourcesRead about laser research on the LTI BlogLearn more about what we offer on the LTI websiteFind out how you can Customize your LTI experience

This is Part Two of a 2-part series, where Daniela shares her story, if you haven't listened to Part One you may want to start there first. We deal with so many different emotions when experiencing vestibular symptoms; when we are misdiagnosed, or mistreated by the medical system, and even comparing our symptoms, treatments, and how we deal with each obstacle as it's introduced into our lives. Our reactions to the symptoms may vary may that be through guilt, self-pity, anger, feeling like a burden, sadness, or any of the other emotions we all deal with, and yes, we all deal with them very differently. Daniela shares how her behavior and emotions changed when symptoms arrived in her life, she is recovering as a better person. Her story is so relatable. I hope you find that too. . Today Daniela shares her story of working in academia as a college professor when her first bothersome symptom of visual disturbances began.  From there the symptoms only increased in intensity and over time she was finally diagnosed with PPPD (Persistent postural perceptual dizziness); neurovascular dizziness caused by jugular compression and thoracic outlet syndrome, along with third window syndrome from cochlear-facial nerve canal dehiscence.  So many things changed her life, but I will save all the details for her to share with you in this Part 1 of a two-part series. If you would like to reach out to Daniela, please find her on ⁠Instagram⁠ https://www.instagram.com/dizzyprof/ To read Daniela's book, "⁠Counterpreservation: Architectural Decay in Berlin since 1989"⁠, please find it on Amazon If you would like to reach out to me, Heather Davies: Email me at menieresmuse@gmail.com ⁠⁠⁠Instagram⁠⁠⁠ ⁠⁠⁠Private Facebook Group⁠⁠⁠ ⁠⁠⁠Leave a voice message⁠⁠⁠ Would you like to JOIN THE MOVEMENT and make a donation in honor of my pledge for ⁠Steps 2 Balance ⁠week, May 21, 2023 through 27th, where we will be walking "together" to raise awareness, your support will also help make sure that when a person gets dizzy, they will get the help they need.  Please make your pledge ⁠here⁠ https://vestibular.salsalabs.org/s2b-2023/p/HeatherDavies For more information on vestibular disorders please visit ⁠⁠⁠VeDA website⁠⁠⁠ at www.vestibular.org ⁠⁠Online Support Groups⁠⁠: Facilitated by Angela S., Lakin, Racheal, Dave, Joy and Marissa The meeting ID and Pass Code are the same for all meetings.  Meeting Id: 841 905 3323 Pass Code: dizzy Meniere's Support Group times: Wednesday 10am CT / 9am ET Wednesday 2pm CT / 1pm ET Wednesday 5pm CT / 4pm ET Wednesday 8:30pm CT / 7:30pm ET Vestibular Zoom Support Group Meetings (for all vestibular disorders): Thursdays at 8pm CT / 7pm ET Thank you for listening! Remember to love yourself, be open to the work, lean on this beautiful community, and lastly believe healing is possible.  See you next week warriors! 

Many have heard one of these variations in our lives, “burning the candle at both ends,” “biting off more than you can chew”,  “spreading yourself too thin” or my personal favorite “you can't pour from an empty cup”.  Today's guest, was like many of the vestibular warriors I speak with,  stressed in our jobs, working insane hours, overextending ourselves, and at times, eating poorly and not getting enough sleep. Self-care was a reward that we gave ourselves for good behavior after we completed a task, like a clean house or some other goal.  I remember myself doing this in the past as well.  Today Daniela shares her story of working in academia as a college professor when her first bothersome symptom of visual disturbances began.  From there the symptoms only increased in intensity and over time she was finally diagnosed with PPPD (Persistent postural perceptual dizziness); neurovascular dizziness caused by jugular compression and thoracic outlet syndrome, along with third window syndrome from cochlear-facial nerve canal dehiscence.  So many things changed her life, but I will save all the details for her to share with you in this Part 1 of a two-part series. In this conversation, we discuss these and many other things: ~ being perfectly imperfect, unintentional gaslighting ~ guilt, shame, imposter syndrome, anxiety, comparison, anxiety, fear, stress ~ being grateful, support at work, single parenting ~ talk therapy, meditation, soft tissue therapy If you would like to reach out to Daniela, please find her on Instagram https://www.instagram.com/dizzyprof/ To read Daniela's book, "Counterpreservation: Architectural Decay in Berlin since 1989", please find it on Amazon If you would like to reach out to me, Heather Davies: Email me at menieresmuse@gmail.com ⁠⁠Instagram⁠⁠ ⁠⁠Private Facebook Group⁠⁠ ⁠⁠Leave a voice message⁠⁠ Would you like to JOIN THE MOVEMENT and make a donation in honor of my pledge for Steps 2 Balance week, May 21, 2023 through 27th, where we will be walking "together" to raise awareness, your support will also help make sure that when a person gets dizzy, they will get the help they need.  Please make your pledge here https://vestibular.salsalabs.org/s2b-2023/p/HeatherDavies For more information on vestibular disorders please visit ⁠⁠VeDA website⁠⁠ at www.vestibular.org ⁠Online Support Groups⁠: Facilitated by Angela S., Lakin, Racheal, Dave, Joy and Marissa The meeting ID and Pass Code are the same for all meetings.  Meeting Id: 841 905 3323 Pass Code: dizzy Meniere's Support Group times: Wednesday 10am CT / 9am ET Wednesday 2pm CT / 1pm ET Wednesday 5pm CT / 4pm ET Wednesday 8:30pm CT / 7:30pm ET Vestibular Zoom Support Group Meetings (for all vestibular disorders): Thursdays at 8pm CT / 7pm ET Thank you for listening! Remember to love yourself, be open to the work, lean on this beautiful community, and lastly believe healing is possible.  See you next week warriors! 

In this episode, Tom Salemi interviews Mark Dickinson, worldwide president at Cerenovus, the neurovascular business at Johnson & Johnson Medtech. Mark Dickinson shares his unique entry into the medical device industry, how he built his career at the global company, and what the company is doing to develop its devices to treat stroke patients. In addition, we'll also have interviews with Paul Grand, CEO of Medtech Innovator, and Jeff Alvarez, chief strategy officer at Moon Surgical. Both will be speaking at DeviceTalks Boston on May 10-11. Go to DeviceTalks.com to register. This episode is sponsored by the Medical Business Unit at TE Connectivity. For more information go to TE.Com/medical. Thanks for listening to this episode of the DeviceTalks Weekly Podcast. You can subscribe to the DeviceTalks Podcast Network on any major podcast application.

With a background as a trauma nurse and experience running clinical research programs, Stacey Pugh brought quite a bit of patient-focused experience with her when she shifted to industry. After several roles in the neurovascular space, now she's leading the charge at Endogenix, which is using pulsed electric fields to treat Type 2 Diabetes. She and host, Geoff Pardo, talk about a medical officer's first experience doing sales, the challenges in affecting change management in primary care, funding businesses with SPACs, and more.  Medtech Talk Links:  Cambridge Healthtech Institute   Medtech Talk  Gilde Healthcare  Endogenex 

Do you ever wonder what it takes to become a successful real estate investor? In today's Passive Income Unlocked episode, we explore the mindset and strategy for success with Aaronn Bress from Liquidity. He shares how he became committed to syndication and building passive income and stresses how a life-threatening event made him realize the importance of financial security. Let's dive in! Aaron Bress, CEO at Liquidity. He is a neuro-interventional physician in Salt Lake City using cutting-edge medicine to treat Neurovascular diseases, commonly stroke, and aneurysms. He is also an entrepreneur passionate about helping others achieve their dreams through passive real estate investing. [00:01 - 04:14] Opening Segment • Investing in syndications and building passive income • A life-threatening event • The concept of having money make money for you [04:15 - 07:16] Closing Segment • Gain financial security and peace of mind • Financial security for the family in case of tragedy Connect with Aaron: Website: Invest with Liquidity  Key Quotes: "Have your money make money for you." - Aaron Bress WANT TO LEARN MORE? Connect with me through LinkedIn. Or send me an email at sujata@luxe-cap.com Visit my website, www.luxe-cap.com, or my YouTube channel. Thanks for tuning in! If you liked my show, LEAVE A 5-STAR REVIEW, like, and subscribe!

Have you ever wondered how to create more stability and passive income without a huge time commitment? Today, Aaron Bress talks about how doctors can leverage their experience in their respective professions to invest in real estate and discuss strategies for taking advantage of compounding interest and investment potential. He touches on some of the challenges of investing, such as limiting beliefs and difficulty finding suitable partners and investments. This episode will give you the insight you need to make informed decisions when investing in real estate, so take advantage of it! Aaron Bress, CEO at Liquidity. He is a neuro-interventional physician in Salt Lake City using cutting-edge medicine to treat Neurovascular diseases, commonly stroke, and aneurysms. He is also an entrepreneur passionate about helping others achieve their dreams through passive real estate investing. [00:01 - 05:56]  Opening Segment • How Aaron got interested in Real Estate Investing The CEO of Liquidity and a neuro-interventional physician • Aaron shares his experience with Airbnb • How real estate syndications offer peace of mind and more control [05:57 - 13:53] Overcome Limiting Beliefs • Semi-passive income from short-term rental properties • The earn, invest and repeat approach • Limiting beliefs can be overcome by staying persistent and meeting people • Understanding the skepticism of doctors and how to overcome it [13:54 - 22:37]Closing Segment • Why real estate is a great asset class Tax benefits, passive income, and appreciation • Investors should set a goal for themselves for how long they want to wait before investing Connect with Aaron: Website: Invest with Liquidity  Key Quotes: “You can make money on your money, or you can make money on your efforts.” - Sujata Shyam “The challenge is getting to know people, networking, and finding that community that works with your investment plan and your vision.” - Aaron Bress “Keep going, keep getting better, keep meeting people, and just go through the process.” - Aaron Bress WANT TO LEARN MORE? Connect with me through LinkedIn. Or send me an email at sujata@luxe-cap.com Visit my website, www.luxe-cap.com, or my YouTube channel. Thanks for tuning in! If you liked my show, LEAVE A 5-STAR REVIEW, like, and subscribe!

A key component of your head-to-toe and focused assessments is the vascular assessment. In this episode I'm sharing tips and real-world examples to help you feel more confident at the bedside. * What type of clinical situations warrant a vascular assessment * Tips for taking a proper blood pressure measurement * Pulse assessment, including a key tip on using the Doppler * General vascular assessment techniques including capillary refill, edema and pain * Neurovascular assessment * The 6 P's of Ischemia * What the Allen test is and how to perform one * Bruits and thrills demystified! Did you enjoy the PodQuiz at the end of the episode? Sign up for Study Sesh and change the way you study! Are you looking for an easier way to learn Med Surg? Enroll in Med Surg Solution and get lessons on 57 key topics as well as out-of-this-world study guides! Want a sneak peek into nursing school so you can be prepared and ready? Crucial Concepts Bootcamp teaches you core foundation concepts, medication math, organizational strategies, study tips and so much more. Get ready for nursing school and enroll in Crucial Concepts Bootcamp today! Learn more about cardiac assessment in Performing A Cardiac Assessment: Episode 250 Learn more about AVMs in AVMs A to Z: Episode 241 Read the article about performing a vascular assessment and view references here. __________  The information, including but not limited to, audio, video, text, and graphics contained on this podcast are for educational purposes only. No content on this podcast is intended to guide nursing practice and does not supersede any individual healthcare provider's scope of practice or any nursing school curriculum. Additionally, no content on this podcast is intended to be a substitute for professional medical advice, diagnosis or treatment. Straight a Nursing is a proud member of the Airwave Media Network. Learn more about your ad choices. Visit megaphone.fm/adchoices

If you've ever had a migraine, you know that the symptoms — splitting headache, nausea, sensitivity to light — mean you're going to want to spend some time in bed, in a dark room. Migraines are flat out debilitating, and the statistics back this up.Migraines are the third most common neurological disorder. They affect as many as a billion people around the world, making them one of the world's 10 most disabling diseases according to the World Health Organization. But for all the misery for those who suffer from migraines, it's been a long haul for scientists to figure out what actually causes these episodes, and more importantly, how to provide relief.We spoke this week with  Gabriella Muwanga, a Stanford graduate student who studies what's actually going on in the brain during a migraine. And for good reason —  Muwanga has suffered from regular migraines herself since childhood and hopes to contribute to finding better treatments for them in the future.LinksMuwanga's research profileThe Tawfik lab at Stanford MedicineThe Airan lab at Stanford MedicineStanford headache specialist demystifies migraine auras (Stanford Scope Blog, 2017)Migraine Treatment Has Come a Long Way (New York Times Well Blog, 2022)ReferencesAhn, A.H. and Basbaum, A.I. Where do triptans act in the treatment of migraine? Pain. 2005 May; 115(1-2): 1–4.Charles, A., Baca, S. Cortical spreading depression and migraine. Nat Rev Neurol 9, 637–644 (2013). Weatherall, M.W. The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis. 2015 May; 6(3): 115–123.Hoffmann, J.,  Baca, S. M., and  Akerman, S. Neurovascular mechanisms of migraine and cluster headache. J Cereb Blood Flow Metab. 2019 Apr; 39(4): 573–594.Episode CreditsThis episode was produced by Michael Osborne, with production assistance by Morgan Honaker and Christian Haigis, and hosted by Nicholas Weiler. Cover art by Aimee Garza.Thanks for listening! Learn more about the Wu Tsai Neurosciences Institute at Stanford and follow us on Twitter, Facebook, and LinkedIn.

En muchas ocasiones, la edad que refleja el DNI no se corresponde con la actitud vital de la persona en cuestión. Todos conocemos algún “viejoven”, jóvenes que aparentan muchos más años de los que tienen y, al revés, personas mayores llenas de vida, con ganas de vivirla y con una mente despierta. Un estudio del Grupo de investigación Neurovascular del Instituto Hospital del Mar de Investigaciones Médicas ha desvelado la relación entre la edad biológica y el envejecimiento cerebral. En "Más cerca” (Radio 5) hemos entrevistado a Joan Jiménez-Balado, autor del estudio. Escuchar audio

Dan Volz, president of the neurovascular business at Medtronic, lays out the dire facts regarding stroke. Less than 10 percent of the 15 million strokes that occur each year worldwide are treated, and the number of strokes grows by 10% each year. In this episode, we'll explore Medtronic's new agreement with Avail Medsystems, which sells access to a network of communication devices that provide audio and video connection to operating rooms. Avail CEO Daniel Hawkins joins in on the conversation explaining how Avail can facilitation collaboration between surgeons, speed training on new life-saving devices, and even help engineers observe procedures so they can develop new critical tools. The pair will discuss how Medtronic is using Avail's products day-to-day as well as part of the company's new Co-Lab Platform to help those developing new neurovascular products outside of Medtronic. Thank you to Cretex Medical for sponsoring this episode. Thank you for listening to the MedtronicTalks Podcast. You can subscribe to this podcast on any major podcast player.

In this episode, Celine Martin, company group chairman, Cardiovascular & Specialty Solutions Group, offers insights from her career at Johnson & Johnson. What are the four variables you need to consider to thrive in a global company. Martin also shares insights on cardiac ablation, neurovascular, and where the company is headed following the acquisition of Abiomed. Paul Grand, CEO of Medtech Innovator, joins as a co-host offering insights on Chris Newmarker's Newsmakers – Moon Surgical, Butterfly Network, Medtronic, Avail Medsystems, Dexcom, and Fresenius Medical. Grand shares a personal connection to one of the companies. Grand, Newmarker and Tom Salemi also share their thoughts on the retirement of Mike Mussallem, CEO of Edwards Lifesciences. Thank you to Nordson Medical for sponsoring this episode. Go to NordsonMedical.com for more information. Thank you for listening to the DeviceTalks Weekly Podcast You can subscribe to this podcast on any major podcast player.

This episode is dedicated to clarification of a podcast between Joe Rogan and Max Lugavere, two popular influencers that have a large audience. They discussed Alzheimer's disease and brain health in general and some of the information that was shared was not accurate, which can be really harmful. This is by no means an attack on Rogan or Lugavere. After listening to the conversation, we think Lugavere may not be quite familiar with the data regarding brain health, and it would be important to set the record straight and share the evidence with people and let them decide what's best for them. Having seen thousands of patients with dementia, whether it's Alzheimer's disease, frontotemporal lobe dementia, Lewy Body Dementia and others, we feel it's our responsibility to share evidence based data as opposed to feel-good, self confirming anecdotes. Relevant references: Ketogenic Diet: Phillips, M. C et al. (2021). Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease. Alzheimer's research & therapy, 13(1), 1-12. Lilamand, M et al. (2022). Efficacy and Safety of Ketone Supplementation or Ketogenic Diets for Alzheimer's Disease: A Mini Review. Frontiers in Nutrition, 1324. Włodarek, D. (2021). Food for thought: the emerging role of a ketogenic diet in Alzheimer's disease management. Expert Review of Neurotherapeutics, 21(7), 727-730. Cronjé, H et al. (2021). Ketogenic therapies in mild cognitive impairment and dementia. Current Opinion in Lipidology, 32(5), 330-332. LDL Cholesterol metabolism and risk of Alzheimer's: Andrews, S et al., collaborators of the Alzheimer's Disease Genetics Consortium. (2021). Causal associations between modifiable risk factors and the Alzheimer's phenome. Annals of neurology, 89(1), 54-65. Olmastroni, E et al. (2022). Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. European Journal of Preventive Cardiology, 29(5), 804-814. Iwagami, M et al. (2021). Blood cholesterol and risk of dementia in more than 1· 8 million people over two decades: a retrospective cohort study. The Lancet Healthy Longevity, 2(8), e498-e506. Tan, Z. S et al. (2003). Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Archives of Internal Medicine, 163(9), 1053-1057. Kivipelto, M et al. (2002). Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Annals of internal medicine, 137(3), 149-155. Zhou, Z et al. (2020). Low-density lipoprotein cholesterol and Alzheimer's disease: a systematic review and meta-analysis. Frontiers in aging neuroscience, 12, 5. Sáiz-Vazquez, O et al. (2020). Cholesterol and Alzheimer's disease risk: a meta-meta-analysis. Brain sciences, 10(6), 386. Wingo, A. P et al. (2022). LDL cholesterol is associated with higher AD neuropathology burden independent of APOE. Journal of Neurology, Neurosurgery & Psychiatry, 93(9), 930-938. The Nigerian Paradox Study: Hall, K et al. (2006). Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology, 66(2), 223-227. Vascular health and Alzheimer's disease: Levit, A et al. (2020). Neurovascular unit dysregulation, white matter disease, and executive dysfunction: the shared triad of vascular cognitive impairment and Alzheimer disease. Geroscience, 42(2), 445-465. The Effect of Lifestyle on Alzheimer's Risk: Dhana, K et al. (2020). Healthy lifestyle and the risk of Alzheimer dementia: Findings from 2 longitudinal studies. Neurology, 95(4), e374-e383.  Risk Reduction of Cognitive Decline and Dementia: WHO Guidelines. Geneva, Switzerland: World Health Organization; 2019.  https://apps.who.int/iris/bitstream/handle/10665/312180/9789241550543-eng.pdf. Accessed December 4, 2019. MIND Diet: Morris, M. C et al. (2015). MIND diet associated with reduced incidence of Alzheimer's disease. Alzheimer's & Dementia, 11(9), 1007-1014. Morris, M. C et al. (2015). MIND diet slows cognitive decline with aging. Alzheimer's & dementia, 11(9), 1015-1022. van den Brink, A. C et al. (2019). The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diets are associated with less cognitive decline and a lower risk of Alzheimer's disease—a review. Advances in Nutrition, 10(6), 1040-1065. Kheirouri, S., & Alizadeh, M. (2021). MIND diet and cognitive performance in older adults: a systematic review. Critical Reviews in Food Science and Nutrition, 1-19. Hosking, D. E et al. (2019). MIND not Mediterranean diet related to 12-year incidence of cognitive impairment in an Australian longitudinal cohort study. Alzheimer's & Dementia, 15(4), 581-589. Melo van Lent, D et al. (2021). Mind diet adherence and cognitive performance in the Framingham heart study. Journal of Alzheimer's Disease, 82(2), 827-839. Dhana, K et al. (2021). MIND diet, common brain pathologies, and cognition in community-dwelling older adults. Journal of Alzheimer's Disease, 83(2), 683-692. Thomas, A et al. (2022). Association of a MIND Diet with Brain Structure and Dementia in a French Population. The Journal of Prevention of Alzheimer's Disease, 1-10. Arjmand, G et al. (2022). Effect of MIND diet intervention on cognitive performance and brain structure in healthy obese women: a randomized controlled trial. Scientific Reports, 12(1), 1-14. Nutrition and Dementia Prevention: Yassine, H. N et al. (2022). Nutrition state of science and dementia prevention: recommendations of the Nutrition for Dementia Prevention Working Group. The Lancet Healthy Longevity, 3(7), e501-e512. Scarmeas, N et al. (2018). Nutrition and prevention of cognitive impairment. The Lancet Neurology, 17(11), 1006-1015.   Publications by Lugavere's mentor, Dr. Richard Isaacson: Isaacson, R. S et al. (2019). Individualized clinical management of patients at risk for Alzheimer's dementia. Alzheimer's & Dementia, 15(12), 1588-1602. Amini, Y., Saif, N., Greer, C., Hristov, H., & Isaacson, R. (2020). The role of nutrition in individualized Alzheimer's risk reduction. Current nutrition reports, 9(2), 55-63.  Isaacson, R. S. (2019). Advances in early diagnosis and treatment strategies in the management of Alzheimer's disease. Journal of Managed Care Medicine, 22(4), 17-21. Berkowitz, C. L., Mosconi, L., Rahman, A., Scheyer, O., Hristov, H., & Isaacson, R. S. (2018). Clinical application of APOE in Alzheimer's prevention: a precision medicine approach. The journal of prevention of Alzheimer's disease, 5(4), 245-252. BOOK: The Alzheimer's Prevention & Treatment Diet: Using Nutrition to Combat the Effects of Alzheimer's Disease. Isaacson, R. S., & Ochner, C. N. (2016). Square One Publishers, Inc. Podcast episodes mentioned: The Proof with Simon Hill: The carnivore diet, veganism and nutrition misinformation | Dr Alan Flanagan.  The Proof with Simon Hill: Debate: Seed Oils And Heart Disease | Tucker Goodrich And Dr Matthew Nagra   Our publications relevant to this topic: Sherzai, A., Edland, S. D., Masliah, E., Hansen, L., Pizzo, D. P., Sherzai, A., & Corey-Bloom, J. (2013). Spongiform change in dementia with Lewy bodies and Alzheimer disease. Alzheimer Disease & Associated Disorders, 27(2), 157-161. Whitehair, D. C., Sherzai, A., Emond, J., Raman, R., Aisen, P. S., Petersen, R. C., & Fleisher, A. S. (2010). Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimer's & Dementia, 6(5), 412-419. Lazar, E., Sherzai, A., Adeghate, J., & Sherzai, D. (2021). Gut dysbiosis, insulin resistance and Alzheimer's disease: review of a novel approach to neurodegeneration. Frontiers in Bioscience-Scholar, 13(1), 17-29. Sherzai, D., & Sherzai, A. (2019). Preventing Alzheimer's: Our most urgent health care priority. American journal of lifestyle medicine, 13(5), 451-461. Sherzai, A. Z., Sherzai, A. N., & Sherzai, D. (2022). A Systematic Review of Omega-3 Consumption and Neuroprotective Cognitive Outcomes. American Journal of Lifestyle Medicine, 15598276221117102. Sherzai, D., Sherzai, A., & Sherzai, A. (2022). Lifestyle Intervention and Alzheimer Disease. The Journal of Family Practice, 71(1 Suppl Lifestyle), eS83-eS89. Sherzai, D., Sherzai, A., Lui, K., Pan, D., Chiou, D., Bazargan, M., & Shaheen, M. (2016). The association between diabetes and dementia among elderly individuals: a nationwide inpatient sample analysis. Journal of Geriatric Psychiatry and Neurology, 29(3), 120-125. Sherzai, A., Sherzai, D., Pilot, M., & Ovbiagele, B. (2016). Prevalence of the Diagnoses of Alzheimer's Dementia, Non-Alzheimer's Dementia and Vascular Dementia Among Hospitalized Stroke Patients: A National Inpatient Sample Analysis, 1999-2012 (P1. 125).   Follow us on social media: Instagram: The Brain Docs @thebraindocs Facebook: The Brain Docs Website: TheBrainDocs.com

This episode features Dr. David Wang, Co-Director of the Neurovascular Division & Petznick Stroke Center at Barrow Neurological Institute; Dr. Robert Lemery, Cardiac Electrophysiologist at Arizona Heart Rhythm Center; & Dr. Vijay Swarup, Director of Cardiac Electrophysiology at Arizona Heart Rhythm Center & Director of Electrophysiology at St. Joseph's Hospital. Here, they discuss details surrounding their collaborative work with The Arizona Brain and Heart Symposium taking place October 21st & 22nd, 2022. Learn more at https://www.barrowneuro.org/patient-care/support-resources/education-seminars/the-arizona-brain-and-heart-symposium/

Drs. Paul Cruci and Allen Gaon give a shocking update on paraesthesia, aguesia and other neurovascular Injuries. They provide advice and best practices to avoid iatrogenic traumas to aid recent graduates and seasoned clinicians alike. This episode offers electrifying discussion and synapses on effective treatment plan methodologies and clinical management of moderate and high-risk cases. What are the management protocols and legal implications when nerve injuries occur? How does imaging influence decision making? What are the recommendations for risk assessment and proper navigation of consent forms? With thoughtful consideration, understanding and experience, Drs. Cruci and Gaon give listeners a taste of their new tier grading system to evaluate the risk of nerve injury associated with endodontic treatment. This informative conversation flows likes a myelinated neuron. Get energized about nerve safety and listen today!Episodes of Endo Voices may include opinion, speculation and other statements not verifiable in the scientific method and do not necessarily reflect the views of AAE or the sponsor(s). Listeners should use their best judgment in evaluating the merits of any content.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The reduction of invasive procedures is one of the main indicators of the advancements being experienced in the field of medicine. It has lowered the risk associated with complex surgeries as well as the recovery time needed by the patient. A big part of it has been the use of robots which increase the precision and decrease the effort required for complex procedures. At the moment, physicians and technology companies are working on making this critical robotics technology widely available.Today, Raymond Turner, Chief Medical Officer of Neurovascular at Siemens Healthineers is joined by three guests – Dr. Monika Killer-Oberpfalzer of Paracelsus Medical University, Dr. Dariusz Dudek, a Cardiologist at Jagiellonian University Hospital in Krakow, Poland, and Dr. Vitor Pereira, Director of Endovascular Research and Innovation at St Michaels Hospital. They'll help us understand the use of robotics technology in endovascular treatment and what's being done to make it more accessible.Stay tuned to learn about the impact that the use of robots is having in the field of medicine. You'll find out how physicians are adjusting to it and the benefits they are getting from it. Additionally, you'll hear about the potential impact that making robots remotely operable would have and the challenges that have to be solved to make that possible.Some Questions Asked:How does a robot function in the interventional lab?How are physicians finding the experience of using joysticks to operate on a patient?What do we need to make the robots operable remotely?How can the bedside team be given the confidence to do what they need to do?What You'll Learn in This Episode:Why interventional procedures required to treat aneurysms are complexHow using endovascular robotic technology has impacted the medical fieldHow neurointerventionalists are trained to use robots in endovascular treatmentThe potential impact that remotely operated robots can haveConnect with Dr. Vitor Mendes Pereira:LinkedInConnect with Dr. Monika Killer-Oberpfalzer:LinkedInConnect with Dr. Dariusz Dudek:WebsiteConnect with Raymond Turner:LinkedIn Hosted on Acast. See acast.com/privacy for more information.

Parenthood changes everyone, but Mark Paul's life took a drastically different turn the moment his oldest child was born. Paul discovered he had a passion for the OR and patient treatment, a realization that convinced him to switch careers to the medical device industry. Today, Paul leads Stryker's neurovascular business which, he says, contains the origins of the stroke treatment industry. In this interview, Paul reviews the strength and strategies of the “micro plumbers” who are helping people who are at risk of suffering a stroke or are trying to find their way back. This episode is sponsored by Resonetics.

This month on Episode 36 of Discover CircRes, host Cynthia St. Hilaire highlights original research articles featured in the April 29 and May 13 issues of Circulation Research. This episode also features a conversation with Dr Patricia Nguyen and Jessica D'Addabbo from Stanford University about their study, Human Coronary Plaque T-cells are Clonal and Cross-React to Virus and Self.   Article highlights:   Zanoli, et al. COVID-19 and Vascular Aging   Wang, et al. JP2NT Gene Therapy in a Mouse Heart Failure Mode   Harraz, et al. Piezo1 Is a Mechanosensor in CNS Capillaries   Zhao, et al. BAT sEVs in Exercise Cardioprotection   Cindy St. Hilaire:        Hi, and welcome to Discover CircRes, the podcast of the American Heart Association's journal, Circulation Research. I'm your host, Dr Cyndy St. Hilaire, from the Vascular Medicine Institute at the University of Pittsburgh. And today, I'll be highlighting the articles from our April 29th and May 13th issues of Circulation Research. I also will speak with Dr Patricia Nguyen and Jessica D'Addabbo from Stanford University about their study, Human Coronary Plaque T-cells are Clonal and Cross-React to Virus and Self.   Cindy St. Hilaire:        The first article I want to share is titled Vascular Dysfunction of COVID 19 Is Partially Reverted in the Long-Term. The first author is Agostino Gaudio and the corresponding author is Luca Zanoli. And they're from the University of Catania. Cardiovascular complications, such as endothelial dysfunction, arterial stiffness, thrombosis and heart disease are common in COVID 19. But how quickly such issues resolve, once the acute phase of the illness has passed, remains unclear. To find out, this group examined aortic and brachial pulse wave velocity, and other measures of arterial stiffness in 90 people who, several months earlier, had been hospitalized with COVID 19. These measurements were compared with data from 180 controls, matched for age, sex, ethnicity and body mass index, whose arterial stiffness had been assessed prior to the pandemic. 41 of the COVID patients were also examined 27 weeks later to assess any changes in arterial stiffness over time. Together, the data showed arterial stiffness was higher in COVID patients than in controls. And though it improved over time, it tended to remain higher than normal for almost a year after COVID.   Cindy St. Hilaire:        This finding could suggest residual structural damage to the arterial walls or possibly, persistent low-grade inflammation in COVID patients. Either way, since arterial stiffness is a predictor of cardiovascular health, its potential longterm effects in COVID patients deserves further longitudinal studies.   Cindy St. Hilaire:        The second article I want to share is titled Gene Therapy with the N-Terminus of Junctophilin-2 Improves Heart Failure in Mice. The first author is Jinxi Wang and the corresponding author is Long-Sheng Song from the University of Iowa. Junctophilin-2 is a protein with a split personality. Normally, it forms part of the heart's excitation contraction coupling machinery. But when the heart is stressed, JP2 literally splits in two, and sends its N-terminal domain, JP2NT, to the nucleus, where it suppresses transcription of genes involved in fibrosis, hypertrophy, inflammation and other heart failure related processes. However, if this stress is severe or sustained, the protective action of JP2NT is insufficient to halt the progressive failure. This group asked. "What if this N-terminal domain could be ramped up using gene therapy to aid a failing mouse heart?"   Cindy St. Hilaire:        To answer this question, they injected adenoviral vectors encoding JP2NT into mice either before or soon after transaortic constriction, or TAC, tack, which is a method of experimentally inducing heart failure. They found, in both cases, that the injected animals fared better than the controls. Animals injected before TAC showed less severe cardiac remodeling than control mice, while those treated soon after TAC exhibited slower loss of heart function with reduced ventricle dilation and fibrosis. These data suggest that supplementing JP2NT, via gene therapy or other means, could be a promising strategy for treating heart failure. And this data provides a basis for future translational studies.   Cindy St. Hilaire:        The third article I want to share is titled Piezo1 Is a Mechanosensor Channel in Central Nervous System Capillaries. The first and corresponding author is Osama Harraz from the University of Vermont. Neurovascular coupling is the process whereby transient activation of neurons leads to an upsurge in local blood flow to accommodate the increased metabolic needs of the cell. It's known that agents released from active neurons trigger changes in local capillaries that prompt vasodilation, but how these hemodynamic changes are sensed and controlled is not entirely clear. This group suspected that the mechanosensory protein Piezo1, a calcium channel that regulates dilation and constriction of other blood vessels, may be involved. But whether Piezo1 is even found in the microcirculation of the CNS was unknown. This group shows that Piezo1 is present in cortical capillaries of the brain and the retina of the mouse, and that it responds to changes in blood pressure and flow.   Cindy St. Hilaire:        Ex vivo preparations of mouse retina showed that experimentally induced changes in hemodynamics caused calcium transients and related currents within capillary endothelial cells, and that these were dependent on the presence of Piezo1. While it is not entirely clear how Piezo1 influences cerebral blood flow, its pressure induced activation of CNS capillary endothelial cells suggest a critical role in neurovascular coupling.   Cindy St. Hilaire:        The last article I want to share is titled Small Extracellular Vesicles from Brown Adipose Tissue Mediate Exercise Cardioprotection. The first authors are Hang Zhao and Xiyao Chen. And the corresponding authors are Fuyang Zhang and Ling Tao from the Fourth Military Medical University. Regular aerobic exercise is good for the heart and it increases the body's proportion of brown adipose tissue relative to white adipose tissue. This link has led to the idea that brown fat, possibly via its endocrinal activity, might somehow contribute to exercise related cardioprotection. Zhao and colleagues now show that, indeed, brown fat produces extracellular vesicles that are key to preserving heart health. While mice subjected to four weeks of aerobic exercise were better protected against subsequent heart injury than their sedentary counterparts, blocking the production of EVs prior to exercise significantly impaired this protection. Furthermore, injection of brown fat derived EVs into the hearts of mice lessened the impact of subsequent cardiac injury.   Cindy St. Hilaire:        The team went on to identify micro RNAs within the vesicles responsible for this protection, showing that the micro RNAs suppressed an apoptosis pathway in cardiomyocytes. In identifying mechanisms and molecules involved in exercise related cardio protection, the work will inform the development of exercise mimicking treatments for people at risk of heart disease or who are intolerant to exercise.   Cindy St. Hilaire:        Lastly, I want to bring up that the April 29th issue of Circulation Research also contains a short Review Series on pulmonary hypertension, with articles on: The Latest in Animal Models of Pulmonary Hypertension and Right Ventricular Failure, by Olivier Boucherat; Harnessing Big Data to Advance Treatment and Understanding of Pulmonary Hypertension, by Christopher Rhodes and colleagues; New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis, by Christophe Guignabert and colleagues; Group 3 Pulmonary Hypertension From Bench to Bedside, by Corey Ventetuolo and colleagues; and Novel Approaches to Imaging the Pulmonary Vasculature and Right Heart, by Sudarshan Rajagopal and colleagues; and Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease, by Jessica Huston and colleagues.   Cindy St. Hilaire:        Today, Dr Patricia Nguyen and Jessica D'Addabbo, from Sanford University, are with me to discuss their study, Human Coronary Plaque T-cells are Clonal and Cross-React to Virus and Self. And this article is in our May 13th issue of Circulation Research. So, Trisha and Jessica, thank you so much for joining me today.   Jessica D'Addabbo:    Thank you for having us.   Patricia Nguyen:         Yes. Thank you for inviting us to your podcast. We're very excited to be here.   Cindy St. Hilaire:        Yeah. And I know there's lots of authors involved in this study, so unfortunately we can't have everyone join us, but I appreciate you all taking the time.   Patricia Nguyen:         This is like a humongous effort by many people in the group, including Roshni Roy Chowdhury, and Xianxi Huang, as well as Charles Chan and Mark Davis. So, we thank you.   Cindy St. Hilaire:        So atherosclerosis, it stems from lipid deposition in the vascular wall. And that lipid deposition causes a whole bunch of things to happen that lead to a chronic inflammatory state. And there's many cells that can be inflammatory. And this study, your study, is really focusing on the role of T-cells in the atherosclerotic plaque. So, before we get into the nitty gritty details of your study, can you share with us, what is it that a T-cell does normally and what is it doing in a plaque? Or rather, let me rephrase that as, what did we know a T-cell was doing in a plaque before your study?   Patricia Nguyen:         So, T-cells, as you know, are members of the adaptive immune system. They are the master regulators of the entire immune system, secreting cytokines and other proteins to attract immune cells to a diseased portion of the body, for example. T-cells have been characterized in plaque previously, mainly with immunohisto chemistry. And their characterization has also been recently performed using single cell technologies. Those studies have been restricted to mainly mirroring studies, studies in mice in their aortic walls, in addition to human carotid arteries. So, it is well known that T cells are found in plaque and a lot of attention has been given to the macrophage subset as the innate immune D. But let's not forget the T-cell because they're actually composed about... 50% in the plaque are T-cells.   Patricia Nguyen:         And we were particularly interested in the T-cell population because we have a strong collaboration with Dr Mark Davis, who's actually the pioneer of T-cell biology and was the first to describe the T-cell receptor alpha beta receptor in his lab in the 1970s. So, he has developed many techniques to interrogate T-cell biology. And our collaboration with him has allowed us and enabled us to perform many of these single cell technologies. In addition, his colleague, Dr Chen, also was pivotal in helping us with the interrogation and understanding of the T-cells in plaque.   Cindy St. Hilaire:        And I think one of the really neat strengths of your study is that you used human coronary artery plaques. So, could you walk us through? What was that like? I collect a lot of human tissue in my lab. I get a lot of aortic valves from the clinic. And it's a lot of logistics. And a lot of times, we're just fixing them, but you are not just fixing them. So, can you walk us through? What was that experimental process from the patient to the Petri dish? And also, could you tell us a little bit about your patient population that you sampled from?   Jessica D'Addabbo:    So, these were coronary arteries that we got from patients receiving a heart transplant. So, they were getting a heart transplant for various reasons, and we would receive their old heart, and someone would help us dissect out the coronary arteries from these. And then, we would process each of these coronary arteries separately. And this happened at whatever hour the hearts came out of the patient.   Jessica D'Addabbo:    So sometime, I was coming in at 3:00 AM with Dr Nguyen and we would be working on these hearts then, because we wanted the samples to be as fresh as possible. So, we would get the arteries. We would digest out the tissue. And then, we would have certain staining profiles that we wanted to look at so that we could put the cells on fax to be able to sort the cells, and then do all the downstream sequencing from there.   Cindy St. Hilaire:        So, in terms of, I don't know, the time when you get that phone call that a heart's coming in to actually getting those single cells that you can either send a fax or send a sequencing, how long did that take, on a good day? Let's talk only about good days.   Jessica D'Addabbo:    Yeah. A lot of factors went into that, sometimes depending on availability of things. But usually, we were ready with all of the materials in advance. So, I'd say it could be anywhere from six to 12 hours, it would take, to get everything sorted. Then, everything after that would happen. But that was just that critical period of making sure we got the cells fresh.   Patricia Nguyen:         So we have to credit the CT surgeons at Stanford for setting up the program or the structure, infrastructure, that enables us to obtain this precious tissue. That is Jack Boyd and Joseph Woo of CT surgery. So, they have enabled human research on hearts by making these tissues available. Because as you know, a transplant... They can say the transplant's happening at 12:00 AM, but it actually doesn't happen until 4:00 AM. And I think it's very difficult for a lab to make that happen all the time. And I think having their support in this paper was critical. And this has allowed us, enabled us, to interrogate kind of the spectrum of disease, especially focusing on T-cells, which are... They make a portion of the plaque, but the plaque itself has not like a million cells that are immune. A lot of them are not immune. So, enabling us to get the tissue in a timely fashion where they're not out of the body for more than 30 minutes enables us to interrogate these small populations of cells.   Cindy St. Hilaire:        That's actually the perfect segue to my next question, which is, how many cells in a plaque were you able to investigate with the single cell analysis? And what was the percentage again of the T-cells in those plaques or in... I guess you looked at different phases of plaque. So, what was that spectrum for the percentage of T-cells?   Patricia Nguyen:         So, for 10X, for example, you need a minimum of 10,000 captured cells. You could do less, but the utility of the 10X is maximized with 10,000. So, many times before the ability to multiplex these tissues, we were doing like capturing 5,000 for example. And the number of cells follows kind of the disease progression, in the sense that as a disease is more severe, you have more immune cells, in general. And it kind of decreases as it becomes more fibrotic and scarred, like calcified. So, it was a bit challenging to get very early just lipid-only cells. And a lot of those, we captured like 3000 or something like that. And efficiency is like 80% perhaps. So, you kind of capture…   Cindy St. Hilaire:        And also, how many excised hearts are going to have early athero? So, it's...   Patricia Nguyen:         Well, there are... nonischemics will have...   Cindy St. Hilaire:        Oh, okay. Okay.   Patricia Nguyen:         So, the range was nonischemic to ischemic.   Cindy St. Hilaire:        Oh great.   Patricia Nguyen:         So, about a portion... I would say one third of the total heart transplants were ischemic. And a lot of them were non ischemic. But as you know, the nonischemic can mix with ischemia. And so, they could have mild to moderate disease in the other arteries, for example, but not severe like 70%/90% obstruction.   Cindy St. Hilaire:        Wow. That's so great. That's amazing. Amazing sample size you have. So T-cell, it's kind of an umbrella term, right? There's many different types of T-cells. And when you start to get in the nitty gritty, they really do have distinct functions. So, what types of T-cells did you see and did you focus on in this study?   Jessica D'Addabbo:    So, the two main types of T-cells are CD4 positive T-cells and CD8 positive T-cells. And we looked at both of these T-cells from patients. We usually sorted multiple plates from each. And then, with 10X, we captured both. But our major finding was actually that the CD8 positive t-cell population was more clonally expanded than the CD4 population, which led us to believe that these cells were more important in the coronary artery disease progression and in the study that we were doing because for a cell to be clonally expanded, it means it was previously exposed to an antigen. And so, if we're finding these T-cells that are clonally expanded in our plaques, then we're hypothesizing that they were likely exposed to some sort of antigen, and then expanded, and then settled into the plaque.   Cindy St. Hilaire:        And when you're saying expansion, are you talking about them being exposed to the antigen in the plaque and expanding there? Or do you think they're being triggered in the periphery and then honing in as a more clonal population?   Patricia Nguyen:         So, that's a great question. And unfortunately, I don't have the answer to that. So basically-   Jessica D'Addabbo:    Next paper, next paper.   Patricia Nguyen:         Exactly. So, we... Interesting to expand on Jessica's answer. Predominantly what was found, as you said, was memory T-cells, so memory T-cells expressing specific markers, so memory versus naive. And these were effector T-cells. And memory meaning they were previously expanded by antigen engagement, and just happened to be in the plaque for whatever reason. We do not know why T-cells specifically are attracted to the plaque, but they are obviously there. And they're in a memory state, if you will. And some of them did display activation markers, which suggested that they clonally expanded to an antigen. What that antigen is, is the topic of another paper. But certainly, it is important to understand that these patients that we recruit, because they were transplant patients, they're not actively infected, right? That is a exclusionary criteria for transplants, right?   Patricia Nguyen:         So, that means these T-cells were there for unclear reasons. Why they're there is unclear. Whether they are your resident T-cells also is unclear, because the definition of resident T-cell still remains controversial. And you actually have to do lineage tracking studies to find out, "Okay, where... Did they come from the bone marrow? Did they come from the periphery? How did they get there?" Versus, "Okay. They were already there and they just expanded, for whatever reason, inside the plaque."   Cindy St. Hilaire:        So, your title... It was a great title, with this provocative statement, "T-cells are clonal and cross react to virus and self." So, tell us a little bit more about this react to virus and self bit. What did your data show?   Jessica D'Addabbo:    So, because of the way we sequenced the T-cell receptor, we were able to have paired alpha and beta chains. And because we knew the HLA type of the patients, we were able to put the sequences that we got out after we sequenced these through an algorithm called GLIPH, which allows us to look at the CDR3 region of the T cell receptor, which is the epitope binding region. And there are certain peptide. They're about anywhere from three to four amino acids long. These are mapped to certain binding specificities to known peptides. And so, basically, we were able to look at which epitopes were most common in our plaques. And we found that after comparing these to other epitopes, that these were actually more binding to virus. Patricia Nguyen:         So let me add to what Jessica stated, and kind of emphasize the value of the data set, if you will. So, this is, I believe, the first study that provides the complete TCR repertoire of coronary plaque, and actually any plaque that I know of, which is special because we know that there is specificity of TCR binding. It's more complicated than the antibody that binds directly from B cells to the antigen, because the T-cells bind processed antigen. So, the antigens are processed by antigen presenting cells like Dendritic cells and macrophages. And they have a specific HLA MHC class that they need to present to. And they need both arms, the antigen epitope and the MHC, to activate the T-cell. So unfortunately, it's not very direct to find the antigen that is actually activating the T-cell because we're only given a piece of it. Right?            Patricia Nguyen:         But we have provided a comprehensive map of all the TCRs that we find in the plaque. And these TCRs have a sequence, an immuno acid sequence. And luckily, in the literature, there is a database of all TCR specificities. Okay. So, armed with our TCR repertoire, we can then match our TCR repertoire with an existing database of known TCR specificities. Surprisingly, the matching TCRs are specific to virus, like flu, EBV and CMB. And also, because this was done in the era of COVID, we thought it would be important to look at the coronavirus database. We did find that there were matches to the coronavirus database. Even though our finding is not specific to SARS, it does lend to some potential mechanistic link there as well.   So, because this is all computational, it is important to validate. So, the importance of validation requires us to put the TCR alpha beta chain into a Jurkat cell, which is a T-cell line that does not have alpha beta chains on it, and then expose it to what we think is the cognate antigen epitote, with the corresponding HLA MHC APC. Because you don't have all those pieces, it will not work. Yes. So importantly, we did find that what we predicted to have the specificity of a flu peptide had specificity to a flu peptide.   Patricia Nguyen:         So then, the important question was, "Okay, these patients aren't infected, right? Why are these things here? Is there a potential cross reactivity with self peptides?"   Patricia Nguyen:         So luckily, our collaborator, Dr Charles Chan, was able to connect us with another computational algorithm that he was familiar with, whereby we were able to take the peptide sequences from the flu and match them with peptide sequencing from proteins that are self and ubiquitous. And we demonstrated, again, these T-cells were activated in vitro. That is why we concluded that there's a potential cross reactivity between self and virus that can potentially lead to thrombosis associated with viral infections. Of course, this all needs to be proved in vivo.   Cindy St. Hilaire:        Sure, sure.   Patricia Nguyen:         It's that first step for other things.   Cindy St. Hilaire:        The other big immune cell that we know is in atherosclerotic plaques and that's macrophages. And they can help to present antigens and things like that. And they also help to chew up the necrotic bits. And so, do you think that this T-cell component is an earlier, maybe disease driving, process or an adaptive process that goes awry as a secondary event? Patricia Nguyen:         So, I'm a fan of the T-cell. So... I'm with team T cell. I would like to think that it is playing an active role in pathology in this case and not a reactive role, in the sense of just being there. I think that the T-cell is actively communicating with other cells within the plaque, and promoting pro fibrotic and pro inflammatory reactions, depending on the T-cell. So, a subset of this paper was looking at kind of the interactions between the T-cell and other cells within the plaque, like macrophages and smooth muscle cells. And as we know, T-cells are activated and they produce cytokines. Those cytokines then communicate to other cells. And we found that, computationally, when you look at the transcriptome, there is a pro-inflammatory signature of the T-cell that resides in the more complex stage. And then, there's an anti-inflammatory signature that kind of resides in the transition between lipid and fibro atheroma, if you will.   Cindy St. Hilaire:        So, do you know, or is it known, how dynamic these populations are? Obviously, the hearts that you got, the samples you got, didn't have active infections. But do you know perhaps even how long ago they happened, or even how soon after there might be an infection or an antigen presented that you could get this expansion? And could that be a real driver of rupture or thrombosis?   Patricia Nguyen:         So, in theory, you would suppose that T-cells expanding and dividing and producing more and more cytokines would then lead to more macrophages coming, more of their production of proteinases that destroy the plaque. Right? So yes, in theory, yes. I think it's very difficult to kind of map the progression of T cell clonality in the current model that we have, because we're just collecting tissues. However, in the future, as organoids become more in science and kind of a primary tissue, where we can... For example, Mark Davis is making organoids with spleen, and also introducing skin to that.   Patricia Nguyen:         And certainly, we could think of an organoid involving the vasculature with immune cells introduced. And so, I think, in the next phase, project 2.0, we can investigate what... like over time, if you could model atherosclerosis and the immune system contribution, T-cells as well as macrophages and other immune cells, you can then kind of map how it happens in humans. Because obviously, mice are different. We know that mice... Actually, the models of transgenic mice do not rupture. It's very hard to make them rupture. Right?   Cindy St. Hilaire:        Well, if you stop feeding them high fat diet, the plaque goes away.   Patricia Nguyen:         For sure, for sure. So I think.. I mean, Mark Davis is a huge proponent of human based research, like research on human tissue. And as a physician scientist, obviously I'm more inclined to do human based research. And Jessica's going to be a physician someday soon. And I'm sure she's more inclined to do human based research. And certainly, the mouse model and in vitro models are great because you can manipulate them. But ultimately, we are trying to cure human diseases.   Cindy St. Hilaire:        Mice are not little humans. That's what we say in my lab. I similarly do a lot of human based stuff and it's amazing how great mice are for certain things, but still how much is not there when we need to really fully recapitulate a disease model.   So, my last question is kind of regarding this autoimmune angle of your findings. And that is, women tend to have more autoimmune diseases than men, but due to the fact that you are getting heart transplants, you've got a whole lot more men in your study than women. I think it was like 31 men to four women. But, I mean, what can you do? It's the nature of heart transplants. But I'm wondering, did you happen to notice...Maybe the sample size perhaps is too small, but were there any differences in the populations of these cells between women and men? And do you think there could be any differences regarding this more prevalence of autoimmune like reactions in women?   Patricia Nguyen:         So, that's an interesting question, but you hit it on the nose when you said "Your sample is defined mainly by men." And in addition, the samples that were women tend to have less disease. And they tend to be nonischemic in etiology. So, I think that kind of restricts our analysis. And perhaps, I guess, future studies could model using female tissues, for example, instead of only male. But the limitation of all human studies is sample availability. And perhaps, human organoid research can be less limited by that. And certainly, mouse research has become more evenly distributed of male and female mice.   Cindy St. Hilaire:        Yeah. Suffice it to say, human research is hard, but you managed to do an amazing and really important study. It was really elegant and well done. Congratulations on what is an epic amount of time. 12-hour experiments are no joke, and really beautiful data. So, thank you so much for joining me today, Dr Nguyen and Miss almost Dr D'Addabbo. Congrats and I'm really looking forward to seeing your future work.   Jessica D'Addabbo:    Thank you so much.   Patricia Nguyen:         Thanks so much.   Jessica D'Addabbo:    Thank you for having us. This is wonderful.   Cindy St. Hilaire:        That's it for the highlights from the April 29th and May 13th issues of Circulation Research. Thank you so much for listening. Please check out the Circ Res Facebook page and follow us on Twitter and Instagram with the handle @Circres and #Discover CircRes. Thank you to our guests: Dr Patricia Nguyen, and soon to be Doctor, Jessica D'Addabbo, from Stanford University.   This podcast was produced by Ishara Ratnayaka, edited by Melissa Stoner, and supported by the editorial team of Circulation Research. Copy text for the highlighted articles was provided by Ruth Williams. I'm your host, Dr Cindy St. Haler. And this is Discover CircRes, you're on the go source for the most exciting discoveries in basic cardiovascular research. This program is copyright of the American Heart Association 2022. The opinions expressed by the speakers of this podcast are their own and not necessarily those of the editors or of the American Heart Association. For more information, visit aha journals.org.  

Daniel Volz, the newly named head of Medtronic's neurovascular group, explains how the company is developing game-changing technologies into devices that will help people who have suffered a stroke or aneurysm. Volz reviews the newest addition to Medtronic's pipeline as well as its innovative deal with Viz.ai, an artificial intelligence provider.

Where are you stuck in your body? As athletes, we turn to body work to ease restrictions and improve our mobility. But only neurovascular release (NVR) addresses the underlying causes of our stuck-ness, helping us rehabilitate old injuries and prevent new ones. So, how does NVR work to cultivate resilience and fine tune our bodies for high performance? With two decades of experience as a manual practitioner, Kier Schumaker is a Licensed Massage Therapist, Board Certified Structural Integrator and Certified Teacher of Anatomy Trains SI. For the past eight years, Kier has been teaching their own unique curriculum on neurovascular release, and they serve as the Director of the NVR Advanced Certification Program. Since COVID, they have adapted their approach to balancing the body to work with clients in remote sessions online. On this episode of Holistic High Performance, Kier joins Daniel to explain how the injuries they sustained as an athlete led to their interest in body work. They describe how structural integration helped them achieve more mobility, but neurovascular release work addressed the underlying issues and facilitated more permanent change. Listen in for insight on why we get stuck in our bodies and learn how Kier's online trainings can help you resolve those restrictions with NVR. What You Will Learn How the injuries Kier sustained as an athlete led to their interest in body work The other modalities Kier tried to alleviate their pain before discovering structural integration How Kier describes SI as landing somewhere between physical therapy and massage How SI helped Kier release their compensations but didn't address their underlying issues Why the subtle touch of osteopathic techniques has such a profound effect on movement What inspired Kier to develop their own neurovascular release protocol What differentiates NVR from other modalities and how it facilitates more permanent change How sprinters, golfers and pitchers can benefit from NVR techniques How Kier shifted her practice during COVID to train practitioners on NVR in a virtual setting How Kier is teaching people a version of the tiger stripes technique to use on themselves The 4 reasons why we get stuck in our bodies and how NVR resolves such restrictions Connect with Kier Schumaker Agile Body Kier's Online Course Offerings Kier on LinkedIn Email learn.nvr@gmail.com Connect with Daniel Christofferson Holistic High Performance Daniel on LinkedIn Resources Kier's Neurovascular Release Online Course Anatomy Trains

Gamechangers LIVE with Special Guest David Ferrera, CEO of The Quantum Fund. David Ferrera is an engineer, entrepreneur, inventor and advisor with more than 25 years experience in the medical device field successfully developing products, founding companies, and managing them from concept through commercialization. He's currently Chief Technology Officer of Balt which is dedicated to advancing therapies in hemorrhagic and ischemic stroke. David co-founded Blockade Medicalin 2011 and was their President and CEO. Blockade was acquired by Balt Extrusionof France in August 2016. Balt designs, manufactures and distributes'Interventional Neuro Radiology' (‘INR') devices such as catheters, stents and coilsthat are essential in treating such conditions as hemorrhagic and ischemic stroke.Prior to co-founding Blockade he was co-founder and Vice President of ProductDevelopment/Clinical Research/General Manager of MindFrame Inc., of Irvine,CA. Mr. Ferrera formed and managed the team that successfully developed thecompany's first acute stroke mechanical thrombectomy product line. MindFramewas acquired by Covidien/ev3 Neurovascular (now Medtronic Neurovascular) in2012. Sergio is a dynamic leader, Speaker and Executive Coach with over twenty years of domestic and international business leadership experience. He is currently CEO of Progress Partners Consulting, a firm specializing in optimizing individual and team performance. He is also the founder of the Peak Performance Method™ training and is Host of the Gamechangers LIVE™ Podcast! CONNECT WITH ME! www.linktr.ee/coachsergio www.sergiotigera.com www.gamechangerslive.co www.thepeakperformancemethod.com www.linkedin.com/in/sergiotigera